Severe Asthma

Respiratory
6
Pipeline Programs
7
Companies
16
Clinical Trials
7 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
3
0
2
1
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
1100%
+ 17 programs with unclassified modality

Competitive Landscape

7 companies ranked by most advanced pipeline stage

AstraZeneca
AstraZenecaCAMBRIDGE, United Kingdom
10 programs
1
TezepelumabPhase 4Monoclonal Antibody1 trial
BRazilian Asthmatics Patients EOSinophilic Profile (BRAEOS)N/A1 trial
BariatricN/A1 trial
Clinical and demOgRaphic Features of Patients With Uncontrolled Severe Asthma in Russia (CORSAR)N/A1 trial
PROPE Severe Asthma Study in EgyptN/A1 trial
+5 more programs
Active Trials
NCT03925415Completed414Est. Oct 2019
NCT03532685Unknown110Est. Feb 2019
NCT06472310Recruiting5,000Est. Jun 2027
+7 more trials
Generate Biomedicines
Generate BiomedicinesSOMERVILLE, MA
2 programs
2
GB-0895Phase 31 trial
GB-0895Phase 31 trial
Active Trials
NCT07359846RecruitingEst. Jan 2029
NCT07276724RecruitingEst. Dec 2028
Upstream Bio
Upstream BioWALTHAM, MA
2 programs
2
VerekitugPhase 21 trial
VerekitugPhase 21 trial
Active Trials
NCT06196879Active Not RecruitingEst. Jun 2026
NCT06966479RecruitingEst. Sep 2027
CT
1 program
1
TQC2731 injectionPhase 21 trial
Active Trials
NCT05472324CompletedEst. Mar 2025
Polarean Imaging
Polarean ImagingNC - Durham
1 program
Hyperpolarized 129 XenonN/A1 trial
Active Trials
NCT06985225RecruitingEst. Dec 2026
Sanofi
SanofiPARIS, France
1 program
Register Schweres Asthma - German Asthma Net e.V.N/A
Novartis
NovartisBASEL, Switzerland
1 program
Swiss Severe Asthma RegisterN/A

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
AstraZenecaTezepelumab
Generate BiomedicinesGB-0895
Generate BiomedicinesGB-0895
Upstream BioVerekitug
Upstream BioVerekitug
Chia Tai TianQing Pharmaceutical GroupTQC2731 injection
Polarean ImagingHyperpolarized 129 Xenon
AstraZenecaClinical and demOgRaphic Features of Patients With Uncontrolled Severe Asthma in Russia (CORSAR)
AstraZenecaPROPE Severe Asthma Study in Egypt
AstraZenecaStudy in Portuguese Hospitals to Describe Patient Characteristics, Treatment Patterns and Outcomes
AstraZenecaPrevalence of the Eosinophilic Phenotype Among Severe Asthma Patients
AstraZenecaSwiss Severe Asthma Register
AstraZenecaBRazilian Asthmatics Patients EOSinophilic Profile (BRAEOS)
AstraZenecaBariatric
AstraZenecaRussian Severe Asthma Registry

Showing 15 of 16 trials with date data

Clinical Trials (16)

Total enrollment: 18,793 patients across 16 trials

NCT06705764AstraZenecaTezepelumab

Tezepelumab in the Treatment of Emergency Room Asthma in Adults (TERAA)

Start: Apr 2026Est. completion: Nov 2026100 patients
Phase 4Not Yet Recruiting
NCT07359846Generate BiomedicinesGB-0895

A Study to Investigate GB-0895 Adjunctive Therapy in Adults and Adolescents With Severe Uncontrolled Asthma (SOLAIRIA-2)

Start: Jan 2026Est. completion: Jan 2029
Phase 3Recruiting
NCT07276724Generate BiomedicinesGB-0895

A Study to Investigate GB-0895 Adjunctive Therapy in Adults and Adolescents With Severe Uncontrolled Asthma (SOLAIRIA-1)

Start: Dec 2025Est. completion: Dec 2028
Phase 3Recruiting
NCT06966479Upstream BioVerekitug

A Long-Term Safety and Efficacy Study of Verekitug (UPB-101) in Adult Participants With Severe Asthma (VALOUR)

Start: May 2025Est. completion: Sep 2027
Phase 2Recruiting
NCT06196879Upstream BioVerekitug

A Study to Investigate the Efficacy and Safety of Verekitug (UPB-101) in Adult Participants With Severe Asthma (VALIANT)

Start: Feb 2024Est. completion: Jun 2026
Phase 2Active Not Recruiting
NCT05472324Chia Tai TianQing Pharmaceutical GroupTQC2731 injection

Evaluate the Efficacy and Safety of TQC2731 Injection in Patients With Severe Asthma.

Start: Sep 2022Est. completion: Mar 2025
Phase 2Completed
NCT06985225Polarean ImagingHyperpolarized 129 Xenon

Evaluation of Ventilation Defects Downstream of Mucus Plugs in Patients With Severe Asthma

Start: Jun 2025Est. completion: Dec 2026
N/ARecruiting
NCT06472310AstraZenecaClinical and demOgRaphic Features of Patients With Uncontrolled Severe Asthma in Russia (CORSAR)

Clinical and demOgRaphic Features of Patients With Uncontrolled Severe Asthma in Russia (CORSAR)

Start: Jun 2024Est. completion: Jun 20275,000 patients
N/ARecruiting
NCT06283290AstraZenecaPROPE Severe Asthma Study in Egypt

PROPE Severe Asthma Study in Egypt

Start: Mar 2024Est. completion: Nov 2024201 patients
N/ACompleted
NCT07159295AstraZenecaStudy in Portuguese Hospitals to Describe Patient Characteristics, Treatment Patterns and Outcomes

Study in Portuguese Hospitals to Describe Patient Characteristics, Treatment Patterns and Outcomes

Start: Aug 2021Est. completion: Nov 202274 patients
N/ACompleted
NCT03931954AstraZenecaPrevalence of the Eosinophilic Phenotype Among Severe Asthma Patients

Prevalence of the Eosinophilic Phenotype Among Severe Asthma Patients

Start: May 2019Est. completion: Nov 2020794 patients
N/ACompleted
NCT03984253AstraZenecaSwiss Severe Asthma Register

Swiss Severe Asthma Register

Start: May 2019Est. completion: Feb 2034600 patients
N/ARecruiting
NCT03925415AstraZenecaBRazilian Asthmatics Patients EOSinophilic Profile (BRAEOS)

BRazilian Asthmatics Patients EOSinophilic Profile (BRAEOS)

Start: Jan 2019Est. completion: Oct 2019414 patients
N/ACompleted
NCT03532685AstraZenecaBariatric

Clinical, Inflammatory and Functional Evaluation of a Population of Severe and Obese Asthmatics: Follow up

Start: May 2018Est. completion: Feb 2019110 patients
N/AUnknown
NCT03608566AstraZenecaRussian Severe Asthma Registry

Russian Severe Asthma Registry

Start: Mar 2018Est. completion: Dec 20227,000 patients
N/AUnknown
NCT06035289AstraZenecaRegister Schweres Asthma - German Asthma Net e.V.

Register Schweres Asthma - German Asthma Net e.V.

Start: Nov 2011Est. completion: Nov 20264,500 patients
N/ARecruiting

Related Jobs in Respiratory

Ausbildung zum Pharmakanten (m/w/d)

Ferring Pharmaceuticals
Kiel, Germany
20h ago

Global Senior Medical Director – Respiratory Pipeline Medical Lead

Pfizer
United States - New York - New York City
Yesterday
$275K - $458K/yr

Praktikant (m/w/d) Marketing Onkologie

Amgen
Germany - Munich
Yesterday

Sr Product Manager, Monarch (1 of 2)

Johnson & Johnson
Santa Clara, California, United States of America
Yesterday
$142K - $245K/yr

Laboratory Assistant (m/w/d)

Ferring Pharmaceuticals
Kiel, Germany
Yesterday

Director Quality Control (m/w/d)

Ferring Pharmaceuticals
Kiel, Germany
Yesterday

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 late-stage (Phase 3) programs — potential near-term approvals
7 actively recruiting trials targeting 18,793 patients
7 companies competing in this space

Related Indications

Asthma(378)Pulmonary Disease, Chronic Obstructive(263)Chronic Obstructive Pulmonary Disease(123)Idiopathic Pulmonary Fibrosis(90)COPD(74)Chronic Obstructive Pulmonary Disease (COPD)(38)Pulmonary Embolism(27)Respiratory Syncytial Virus Infections(26)Lung Diseases, Interstitial(19)Pulmonary Fibrosis(15)